Because the optimal adjuvant ET for HER2+/HR+ patients remains unclear, investigators in the Short-HER trial (853 patients with HR+ breast cancer were included) evaluated the impact of ET type on DFS in patients with HER2+/HR+ breast cancer (NCT00629278). This evidence concerns the gene ERBB2 and breast carcinoma.